New antibody combo aims to treat brain lymphoma
NCT ID NCT05351593
First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time
Summary
This trial investigates a combination of two drugs—tafasitamab, an antibody given by IV, and lenalidomide, an oral medication—for people with relapsed central nervous system (CNS) lymphoma. The study includes up to 35 participants and is the first to test this antibody in CNS lymphoma, also exploring whether tafasitamab can help open the blood-brain barrier. The goal is to find the safest and most effective dose and to see if the combination can shrink tumors or keep the disease stable.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a combination of tafasitamab (an antibody given intravenously) and lenalidomide (an oral immunomodulatory drug)
- What this could lead to
- If successful, this could offer a new treatment option for people with relapsed central nervous system lymphoma, a hard-to-treat cancer.
- What could go wrong
- This is an early-phase trial with only 35 participants, so results may not apply broadly. The combination may cause significant side effects, and it is not yet known if it will improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CNS LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California, San Francisco
RECRUITINGSan Francisco, California, 94143, United States
Contact Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a cancer drug shrink recurrent brain tumors?
- New cocktail aims to shrink brain tumors
- New cocktail targets brain lymphoma: early trial launches
- New hope for Hard-to-Treat brain cancer: targeted radiation trial launches
- New cell therapy takes on hard-to-treat brain lymphoma in early trial
- Could less chemo be better? new trial aims to reduce treatment burden for brain lymphoma